HERMES PHARMA
HERMES PHARMA is a German specialty CDMO that develops and manufactures user-friendly oral dosage forms — effervescent and chewable tablets, orally disintegrating granules, instant drinks, and lozenges — for global pharmaceutical and nutraceutical companies from GMP facilities in Germany and Austria.
- Company typePrivate
- Founded1970
- HeadquartersPullach, Germany
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What HERMES PHARMA does
HERMES PHARMA GmbH is a privately held German Contract Development and Manufacturing Organization (CDMO) specializing in user-friendly oral dosage forms, headquartered in Pullach, Germany, with GMP-certified manufacturing facilities in Wolfratshausen, Germany and Wolfsberg, Austria, and 501-1,000 employees. The company was spun out from HERMES Arzneimittel GmbH on July 1, 2021 as a separate legal entity within the Johannes Burges Group and now operates as an independent CDMO serving pharmaceutical companies and nutraceutical/dietary supplement producers globally.
The core product platform spans five differentiated oral dosage forms — effervescent tablets, chewable tablets, orally disintegrating granules, instant drinks, and lozenges — backed by proprietary technologies in taste masking, granulation, flavoring, serialization, and packaging (including a two-step desiccant stopper and child-resistant senior-friendly stick packs). A December 2024 patent on effervescent manufacturing and ongoing BSFZ research excellence recognition indicate active R&D investment. Service modules extend across the full pharmaceutical value chain: project management, R&D, formulation, analytical services, clinical studies, regulatory services, sourcing, manufacturing, quality management, and logistics/order management.
The business model is professional-services B2B revenue under quote-based pricing. Customers are enterprise pharmaceutical and nutraceutical companies seeking co-development, in-licensing, or outsourced manufacturing of user-friendly dosage forms. Go-to-market is direct enterprise field sales supplemented by presence at CPHI Worldwide, Vitafoods Europe, and industry association memberships (DCAT, CHPA). Marketing emphasizes sustainability (EcoVadis Silver Medal in 2019, 2022, 2023, 2025) and patient compliance for the more than 50% of consumers who have difficulty swallowing conventional tablets.
HERMES PHARMA firmographics
Firmographics- Name
- HERMES PHARMA
- Legal name
- HERMES PHARMA GmbH
- Website
- https://hermes-pharma.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- HERMES PHARMA is a German specialty CDMO that develops and manufactures user-friendly oral dosage forms — effervescent and chewable tablets, orally disintegrating granules, instant drinks, and lozenges — for global pharmaceutical and nutraceutical companies from GMP facilities in Germany and Austria.
- Ownership category
- akta.pro rank
HERMES PHARMA industry classification
Industry- Product category
- Contract Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where HERMES PHARMA is headquartered
LocationHeadquarters
- HQ city
- Pullach
- HQ country
- Germany
- HQ region
- Europe
Offices3 records
Markets served
HERMES PHARMA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing (CDMO): HERMES PHARMA operates as a CDMO offering full-service pharmaceutical development and manufacturing under GMP. Revenue is generated through project-based development fees, formulation services, analytical services, clinical studies, regulatory services, and manufacturing of user-friendly oral dosage forms for pharmaceutical and nutraceutical companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
HERMES PHARMA product offering
Product offeringCore offering
HERMES PHARMA is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures user-friendly oral dosage forms including effervescent tablets, chewable tablets, orally disintegrating granules, instant drinks, and lozenges. The company offers end-to-end services covering the entire pharmaceutical value chain from project management, R&D, formulation development, analytical and clinical studies through regulatory services, sourcing, GMP-certified manufacturing, quality management, and logistics. Its customers are pharmaceutical and nutraceutical companies seeking differentiated, easy-to-swallow drug delivery formats.
Product overview
HERMES PHARMA is a Contract Development and Manufacturing Organization (CDMO) offering a one-stop-shop platform for user-friendly oral dosage forms. The core product portfolio comprises five distinct dosage forms: Orally Disintegrating Granules, Chewable Tablets, Effervescent Tablets, Instant Drinks, and Lozenges, all designed to address swallowing difficulties experienced by over 50% of patients. The company also offers HERMES NutriCaps as a novel capsule-based delivery system for food supplements. These products are supported by integrated service modules including Project Management, R&D, Manufacturing, Regulatory Services, Quality Management, and Supply Chain/Logistics. The portfolio is differentiated by pioneering technologies in Flavoring, Taste Masking, Granulation, and Packaging, with featured product lines focused on Magnesium supplementation and Macrogol-based laxatives. The company operates GMP-certified manufacturing facilities in Germany and Austria, serving pharmaceutical and healthcare companies globally.
Differentiator
Problem solved
Functional benefit
Brands
- HERMES NutriCaps: A novel and innovative way to deliver food supplements, launched at Vitafoods Europe 2019. Finalist for the NutraIngredients Awards 2019 in the category 'Editors Award for Functional Food Innovation'.
Products and services
- Effervescent Tablets Tablets that dissolve in water to create a pleasant-tasting drink, capable of delivering large quantities or multiple APIs in a single dose, for pharmaceutical and nutraceutical companies.
- Orally Disintegrating Granules
Quantifiable outcome
- More than 50% of people have difficulties swallowing conventional tablets and capsules
- +2 more outcomes
Companies that use HERMES PHARMA
Customer profileSegments3 records
Ideal customer profiles2 records
HERMES PHARMA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
HERMES PHARMA partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor.
- Drug, Chemical & Associated Technologies Association (DCAT)minorIndustry membership organization with 500+ global corporate members in pharmaceutical development and manufacturing. HERMES PHARMA joined to expand network of industry partners and drive innovation in user-friendly dosage forms.
- INNOJET Herbert Hüttlin, RCPE, and Karl Franzens UniversityminorResearch partnership for developing new taste-masking technologies and approaches to increase patient compliance and improve production processes for user-friendly pharmaceuticals. Focus on odor and taste technologies for dosage forms that dissolve in the mouth.
- Consumer Healthcare Products Association (CHPA)minorUS industry association for consumer healthcare products. HERMES PHARMA joined to support commitment to making medicines more user-friendly in the US market.
- Oxford PharmascienceminorPartnership to license and develop a range of OXP zero ibuprofen products using HERMES PHARMA's user-friendly dosage form expertise. Heads of Terms signed for collaboration.
Scale indicators5 records
Recent moves8 records
Expansion highlights4 records
HERMES PHARMA competitors and assessment
Company assessmentDirect peers
- Aenova: German-headquartered CDMO offering solid, semi-solid, and liquid dosage form development and manufacturing for pharma and nutraceutical customers. Direct peer with comparable B2B CDMO model, GMP-certified EU facilities, and similar mid-sized positioning serving European and global pharma clients.
- Delpharm: French pharmaceutical CDMO with European manufacturing network specializing in solid, liquid, sterile, and semi-solid dosage forms. Direct peer competing for similar pharma and consumer health contract manufacturing engagements across Europe.
- NextPharma: European CDMO providing contract development and manufacturing of oral and specialty pharmaceutical dosage forms including pellets, granules, and modified-release formulations. Directly comparable in CDMO service scope and European customer base.
- Hovione: Portuguese CDMO specializing in API development and oral dosage form manufacturing with strong technology and particle engineering capabilities. Specialized CDMO peer with comparable service depth in oral solid dose development and manufacturing.
- Alcami: U.S.-based CDMO offering sterile injectable, oral solid dose, and analytical development services to pharma clients. Mid-sized CDMO peer competing for similar contract manufacturing engagements in the pharmaceutical value chain.
Broad incumbents
- Recipharm: Swedish-headquartered global CDMO (now part of EQT) offering contract development and manufacturing across multiple dosage forms including solids, semi-solids, steriles, and APIs. Broader incumbent with wider modality coverage and larger scale than HERMES PHARMA.
- Catalent: U.S.-headquartered global CDMO giant offering softgel, oral solid, biologics, and cell therapy contract services across a worldwide manufacturing network. Larger incumbent operating well beyond HERMES PHARMA's niche but addressing the same pharma contract manufacturing demand pool.
- Lonza: Swiss-listed global CDMO leader offering contract development and manufacturing for small molecules, biologics, and cell therapies. Overlapping CDMO business with much broader capabilities and geographic footprint than HERMES PHARMA.
- Piramal Pharma Solutions: India-headquartered CDMO division of Piramal Pharma offering contract development and manufacturing of APIs and finished dosage forms across global facilities. Larger CDMO peer operating in pharmaceutical manufacturing outsourcing with comparable customer segments.
- Patheon / Thermo Fisher Pharma Services: Global CDMO brand within Thermo Fisher Scientific offering small and large molecule contract development and manufacturing services. Broad incumbent with global scale and broader service portfolio than HERMES PHARMA.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
HERMES PHARMA social profiles
Digital presenceHERMES PHARMA financial estimates
Financial estimateRevenue estimate
Valuation estimate
HERMES PHARMA leadership team
Management profileNumber of profiles
Profiles7 records
HERMES PHARMA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HERMES PHARMA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HERMES PHARMA
What does HERMES PHARMA do?
HERMES PHARMA is a Contract Development and Manufacturing Organization (CDMO) that develops and manufactures user-friendly oral dosage forms including effervescent tablets, chewable tablets, orally disintegrating granules, instant drinks, and lozenges. The company offers end-to-end services covering the entire pharmaceutical value chain from project management, R&D, formulation development, analytical and clinical studies through regulatory services, sourcing, GMP-certified manufacturing, quality management, and logistics. Its customers are pharmaceutical and nutraceutical companies seeking differentiated, easy-to-swallow drug delivery formats.
Is HERMES PHARMA a public or private company?
HERMES PHARMA is a private company. It is classified as corporate owned and is currently operating.
When was HERMES PHARMA founded?
HERMES PHARMA was founded in 1970. It employs 501 to 1,000 people.
Where is HERMES PHARMA based?
HERMES PHARMA is headquartered in Pullach, Germany, in the Europe region.
How does HERMES PHARMA make money?
One revenue line is on record: contract Development and Manufacturing (CDMO).
Who are HERMES PHARMA's main competitors?
Direct peers on record are Aenova, Delpharm, NextPharma, Hovione and Alcami. Broad incumbents are Recipharm, Catalent, Lonza, Piramal Pharma Solutions and Patheon / Thermo Fisher Pharma Services.
Does HERMES PHARMA have an API?
No public API is recorded for HERMES PHARMA.
What industry is HERMES PHARMA in?
HERMES PHARMA's product category is Contract Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.